搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按时间排序
按相关度排序
C&EN
6 小时
US EPA names 2024 Green Chemistry Challenge Awards recipients
Awardees were recognized for developing renewable lubricant base oils and ethyl acetate, more environmentally-friendly ...
precisionmedicineonline
7 小时
FDA Panel Finds Limited Immunotherapy Benefit in PD-L1-Negative Gastric, Esophageal Cancer
The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties.
The Pharma Letter
16 小时
FDA panel votes against broader use of checkpoint blockers
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a ...
Medpage Today on MSN
23 小时
No Benefit for PD-1 Inhibitors in Certain Gastroesophageal Cancers, FDA Panel Says
The Oncologic Drugs Advisory Committee (ODAC) decided 10-2 with one abstention that PD-1 inhibitors do not have a favorable ...
The Pharma Letter
1 天
Miss for Merck’s favezelimab combo in colorectal cancer
Merck's Phase III KEYFORM-007 trial, testing a combination of favezelimab and Keytruda, failed to meet its primary endpoint ...
Pharmaceutical Technology
1 天
MHLW approves MSD’s KEYTRUDA for lung and urothelial cancers
The Japanese MHLW has granted approval for MSD’s KEYTRUDA (pembrolizumab) for lung and urothelial cancer indications.
Pharmabiz
1 天
Merck’s Keytruda gets new approvals in Japan for certain patients with NSCLC and ...
Rahway, New Jersey Thursday, September 26, 2024, 09:00 Hrs [IST] ...
precisionmedicineonline
2 天
FDA Expert Panel to Consider Limiting Gastric, Esophageal Cancer Immunotherapies to PD-L1 ...
The ODAC will weigh risk-benefit analyses from the FDA and sponsors on Keytruda, Opdivo, and Tevimbra when given with chemo in all comers and in PD-L1-positive subgroups.
2 天
Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study
Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of ...
BioSpace
2 天
Merck’s Keytruda Combo Fails in Phase III Colorectal Cancer Study
Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for ...
BioSpace
2 天
FDA Considers Narrowing Label of PD-1 Drugs in Stomach Cancer Ahead of Adcomm Meeting
If approved, the potential restrictions would impact Merck’s Keytruda and Bristol Myers Squibb’s Opdivo, which are marketed ...
TheDerrick.com
2 天
Reality TV star Julie Chrisley to be re-sentenced in bank fraud and tax evasion case
A federal judge is set to re-sentence reality TV star Julie Chrisley on Wednesday after an appeals court ordered a new ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈